1-9 of 9
re-ly trial
Close
Sort by
Journal Articles

Measuring the Anticoagulation Effects of Exosite I Thrombin Inhibitors: Utility and Limitations of Clotting Assays, Thromboelastography, and Calibrated Automated Thrombography

Matthew Bunce, PhD, Zheng Huang Devine, PhD, Madhu Chintala, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1115.
https://doi.org/10.1182/blood.V130.Suppl_1.1115.1115
Published: 2017
Journal Articles

Comparison of Stroke- and Bleed-Specific Healthcare Resource Utilization and Costs Among Patients with Non-Valvular Atrial Fibrillation, Newly Treated with Dabigatran or Warfarin

Xue Song, PhD, Pranav Gandhi, BPharm, MS, PhD, Adrienne M Gilligan, PhD, Prachi Arora, BPharm, MS, Caroline Henriques, MPH, Cheng Wang, MD PhD, Stephen Sander, PharmD, David M Smith, PhD
Journal: Blood
Blood (2016) 128 (22): 532.
https://doi.org/10.1182/blood.V128.22.532.532
Published: 2016
Journal Articles

Do the Safety and Efficacy Outcomes Reported in the Clinical Trials of Direct Oral Anticoagulants (DOAC) Translate to the Real-World?

Shammim Haji, MPharm, Jignesh P Patel, PhD, Vivian Auyeung, PhD, Lara N Roberts, MD, Julia Czuprynska, MBBS, Raj K Patel, MD, Roopen Arya, PhD
Journal: Blood
Blood (2015) 126 (23): 2335.
https://doi.org/10.1182/blood.V126.23.2335.2335
Published: 2015
Journal Articles

Comparison of Medical Costs Avoided When New Oral Anticoagulants Are Used for the Treatment of Patients with Atrial Fibrillation and Venous Thromboembolism in the U.S

Alpesh N Amin, MDMBA, Amanda Bruno, PhD MPH, Jeffrey Trocio, MPH, Jay Lin, PhD MBA, Melissa Lingohr-Smith, PhD
Journal: Blood
Blood (2014) 124 (21): 2181.
https://doi.org/10.1182/blood.V124.21.2181.2181
Published: 2014
Journal Articles

Dabigatran Etexilate and Risk Of Myocardial Infarction, Major Bleeding and All-Cause Mortality: A Systematic Review and Meta-Analysis Of Randomized Controlled Trials

Jonathan Douxfils, Pharm D, PhD Student, Fanny Buckinx, François Mullier, PhD, Valentine Minet, Pharm D, PhD Student, Véronique Rabenda, Jean-Yves Reginster, Professor, Christian Chatelain, Professor, Philippe Hainaut, Professor, Olivier Bruyère, Professor, Jean-Michel Dogné, Professor
Journal: Blood
Blood (2013) 122 (21): 3633.
https://doi.org/10.1182/blood.V122.21.3633.3633
Published: 2013
Journal Articles

Comparison of Cost-Effectiveness of Anticoagulation with Dabigatran, Rivaroxaban and Apixaban in Patients with Non-Valvular Atrial Fibrillation Across Countries

Martin Krejczy, Job Harenberg, Prof., Dr., Svetlana Marx, Konrad Obermann, Prof., Dr., Martin Wehling, Prof., Dr.
Journal: Blood
Blood (2012) 120 (21): 1164.
https://doi.org/10.1182/blood.V120.21.1164.1164
Published: 2012
Journal Articles

Real Life Efficacy and Safety of Dabigatran for Stroke Prevention in Atrial Fibrillation – First Results of the Prospective Noac Registry (NCT01588119)

Vera Gelbricht, Sebastian Werth, MD, Christina Koehler, Ulrike Haensel, Luise Tittl, Ines Beyer-Westendorf, Thomas Schreier, Jan Beyer-Westendorf, MD
Journal: Blood
Blood (2012) 120 (21): 502.
https://doi.org/10.1182/blood.V120.21.502.502
Published: 2012
Journal Articles

Indirect Comparisons of the New Oral Anticoagulants in Patients with Non-Valvular Atrial Fibrillation

Shabnam Zolfaghari, Jr., M.Sc., Job Harenberg, Prof., Dr., Svetlana Marx, Martin Wehling, Prof., Dr.
Journal: Blood
Blood (2012) 120 (21): 4363.
https://doi.org/10.1182/blood.V120.21.4363.4363
Published: 2012
Journal Articles

Management and Outcomes of Major Bleeding On Dabigatran or Warfarin

Ammar Majeed, Hun-Gyu Hwang, Martina Brueckmann, MD, Stuart Connolly, MD, John Eikelboom, Michael Ezekowitz, MB, ChB, DPhil, Lars Wallentin, MD, PhD, Salim Yusuf, FRCPC, DPhil, Sam Schulman, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 19.
https://doi.org/10.1182/blood.V120.21.19.19
Published: 2012